chufangao/CTO huggingface dataset:
Clinical trial NCT02533180: Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation
Official title: Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Operational Tolerance Following Liver Transplantation in Adults (ITN056ST)
Acronym: OPTIMAL
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 100.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-12-15
Primary completion date: 2020-02-10
Completion date: 2022-07-08
Clinical trial NCT04828174: Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies
Official title: The Safety and Clinical Efficacy of Human TRBC1 CAR-T Cell Therapy for Patients With Relapsed/Refractory TRBC1 Positive T Cell Hematological Maliganacies
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: The trial was suspended due to the inability to enroll qualified participants
Enrollment: 9.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2021-03-31
Primary completion date: 2023-11-26
Completion date: 2023-11-26
Plan to share individual participant data: NO
Clinical trial NCT04781374: Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer
Official title: A Phase 2 Study of Neratinib in Patients With Metastatic Castration Resistant Prostate Cancer and Increased Human Epithelial Growth Factor Receptor 2 (HER2) Signaling
Sponsor: Beth Israel Deaconess Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Withdrawal of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-05-21
Primary completion date: 2021-09-24
Completion date: 2021-09-24
Plan to share individual participant data: YES
IPD sharing description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD time frame: Data can be shared no earlier than 1 year following the date of publication
IPD access criteria: Contact the Beth Israel Deaconess Medical Center Technology Ventures Office at tvo@bidmc.harvard.edu
Clinical trial NCT05338723: Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients
Official title: Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients
Sponsor: Tanta University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-15
Primary completion date: 2023-09-15
Completion date: 2023-09-15
Plan to share individual participant data: NO
Clinical trial NCT03991208: Malarone Pharmacokinetics Under Simulated Physiologic Stressors of Deployment
Official title: Malarone Pharmacokinetics Under Simulated Physiologic Stressors of Deployment
Acronym: MPUSPSD
Sponsor: Walter Reed Army Institute of Research (WRAIR) (FED)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Unable to recruit
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-24
Primary completion date: 2021-05-23
Completion date: 2021-05-23
Clinical trial NCT05087381: Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community
Official title: Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community With Fluvoxamine, Bromhexine, Cyproheptadine, and Niclosamide in Decreasing Recovery Time
Sponsor: Chulalongkorn University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 1200.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-10-01
Primary completion date: 2022-06-21
Completion date: 2022-06-21
Plan to share individual participant data: NO
Clinical trial NCT06147908: Clinical Trial to Evaluate the Pharmacokinetic Characteristics of DW5221 and DW5221-R
Official title: A Bioequivalence Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety After Administration of DW5221 and DW5221-R in Healthy Adult Male Volunteers
Sponsor: Daewon Pharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 54.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-07-01
Primary completion date: 2022-10-26
Completion date: 2022-11-17
Clinical trial NCT03832816: Behavioral and Physiological Effects of THC and CBD
Official title: Behavioral and Physiological Effects of delta9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: cancellation of funding contract
Enrollment: 0.0 (ACTUAL)
Number of arms: 8.0
Start date: 2019-12-31
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Clinical trial NCT03860974: Serratus Plane Versus Paravertebral Nerve Blocks for Breast Surgery
Official title: A Randomized, Subject-Masked, Active-Controlled, Parallel-Arm Clinical Trial Comparing Serratus Plane and Paravertebral Nerve Blocks
Sponsor: University of California, San Diego (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 100.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-09
Primary completion date: 2021-02-12
Completion date: 2021-02-13
Limitations and caveats: \*\* Regarding the time from nerve block placement until block resolution, this outcome was erroneously left off of the case report forms, so we did not collect the data for this outcome measure.
Plan to share individual participant data: NO
Clinical trial NCT04540705: A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
Official title: A Phase 1 Study to Compare Bempegaldesleukin Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (mRCC) (PIVOT IO 011)
Acronym: PIVOT IO 011
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-11
Primary completion date: 2024-01-18
Completion date: 2024-01-18
Clinical trial NCT03369717: Use of Perioperative Antibiotics in Endoscopic Sinus Surgery
Official title: Use of Perioperative Antibiotics in Endoscopic Sinus Surgery
Sponsor: Montefiore Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: SUSPENDED 
Why stopped: Expired IRB approval since 05/07/2020
Enrollment: 400.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2018-08-01
Primary completion date: 2023-01-31
Completion date: 2023-07-31
Plan to share individual participant data: NO
Clinical trial NCT04472819: The Single, Multiple Dose and Food Effect Study of SHR2285 Tablets on Pharmacokinetics and Pharmacodynamics in Healthy Subjects
Official title: A Phase I, Randomized, Double -Blinded, Placebo-Controlled, Single and Multiple Dose and Food Effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR2285 Tablets in Healthy Subjects
Sponsor: Jiangsu HengRui Medicine Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 104.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-08-28
Primary completion date: 2021-05-31
Completion date: 2021-05-31
Plan to share individual participant data: NO
Clinical trial NCT03355326: Evaluation of Glycerin Suppositories to Improve Bowel Function in Gastroschisis
Official title: Evaluation of Routine Administration of Glycerin Suppositories to Improve Bowel Function in Patients With Uncomplicated Gastroschisis
Sponsor: Indiana University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Unable to sufficiently recruit candidates
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-01
Primary completion date: 2020-10-01
Completion date: 2020-10-01
Plan to share individual participant data: NO
Clinical trial NCT03864627: A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis
Official title: A Randomized, Double-blind, Placebo-controlled, Multicentre Phase 2 Study to Evaluate the Safety and Tolerability of Subcutaneous MOR106 Administered Concomitantly With Topical Corticosteroids for Eight Weeks, in Adult Subjects With Moderate to Severe Atopic Dermatitis
Acronym: GECKO
Sponsor: Galapagos NV (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: MOR106 clinical development in atopic dermatitis was stopped for futility
Enrollment: 33.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-25
Primary completion date: 2020-02-27
Completion date: 2020-02-27
Baseline population: The safety analysis set included all participants who received at least one dose of investigational medicinal product (IMP).
Limitations and caveats: The study was terminated as MOR106, clinical development in atopic dermatitis was stopped for futility.
Plan to share individual participant data: NO
Clinical trial NCT04258592: 18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors
Official title: 18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors: a Phase I PET/CT Study
Sponsor: Universitaire Ziekenhuizen KU Leuven (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Insufficient recruitment
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-02-07
Primary completion date: 2022-07-07
Completion date: 2022-07-07
Plan to share individual participant data: NO
Clinical trial NCT01814813: Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Official title: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Sponsor: Alliance for Clinical Trials in Oncology (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: DSMB futility analysis
Enrollment: 90.0 (ACTUAL)
Number of arms: 3.0
Start date: 2013-05-31
Primary completion date: 2017-04-03
Completion date: 2023-05-01
Clinical trial NCT04539262: Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
Official title: A Phase 1b/2a Study in Participants With Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 156.0 (ACTUAL)
Number of arms: 8.0
Start date: 2020-09-14
Primary completion date: 2021-02-26
Completion date: 2021-03-22
Baseline population: The Safety Analysis Set included all participants who were randomized into the study and received at least 1 dose of study treatment.
Plan to share individual participant data: NO
Clinical trial NCT03315897: Effects of Erythropoietin on Cognition and Neural Activity in Mood Disorders
Official title: Effects of Erythropoietin on Cognitive Functions and Neural Activity in Cognitively Impaired Remitted Patients With Bipolar Disorder or Recurrent Depressive Disorder and Healthy People: Study Protocol for a Randomized, Controlled Trial
Acronym: PreTEC-EPO
Sponsor: Mental Health Services in the Capital Region, Denmark (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 103.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-07-05
Primary completion date: 2022-10-01
Completion date: 2022-10-01
Plan to share individual participant data: NO
Clinical trial NCT04742348: Research on Translational Outcomes of Alcohol (Project RETRO)
Official title: Research on Translational Outcomes of Alcohol (Project RETRO)
Sponsor: University of Washington (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: COVID-19 and expiration of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-02-28
Primary completion date: 2023-08-31
Completion date: 2023-08-31
Clinical trial NCT04155047: A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.
Official title: A Randomized, Double-blind, Placebo-controlled, 2-Way Crossover Study of the Effect of a Single Dose of Glycopyrrolate Inhalation Solution (GIS) on Lung Hyperinflation in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Sponsor: Sunovion Respiratory Development Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 44.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-07
Primary completion date: 2020-03-31
Completion date: 2020-03-31
Plan to share individual participant data: YES
IPD sharing description: IPD for this study may be made available upon request via the Clinical Study Data Request site.
IPD time frame: IPD will be made available upon request within 12 months of posting the study results on ct.gov.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT04583735: A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease
Official title: A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA® in Treating Patients With Chronic (Inactive) Thyroid Eye Disease
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 62.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-02
Primary completion date: 2023-03-17
Completion date: 2023-10-12
Baseline population: Intent-to-treat (ITT) population included all randomized participants to receive study drug.
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Clinical trial NCT04007367: A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder
Official title: A Phase 3, Randomized, Double-Blind, Placebo-controlled Study of the Efficacy and Safety of SAGE-217 With a Fixed, Repeated Treatment Regimen on Relapse Prevention in Adults With Major Depressive Disorder
Sponsor: Biogen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Internal company decision
Enrollment: 53.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-08-06
Primary completion date: 2020-01-06
Completion date: 2020-01-06
Baseline population: Safety Set included all participants who were administered the study drug.
Limitations and caveats: The study was stopped prematurely and therefore data was not collected and analyzed for any efficacy outcome measure planned for the DB Phase of the study.
Plan to share individual participant data: YES
IPD sharing description: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Clinical trial NCT03347526: A Novel Approach to Infantile Spasms
Official title: A Novel Approach to Infantile Spasms: Combined Cosyntropin Injectable Suspension, 1 mg/mL and Vigabatrin Induction Therapy
Sponsor: University of Colorado, Denver (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: SUSPENDED 
Why stopped: Study on enrollment hold as a precaution per the pharmaceutical company.
Enrollment: 394.0 (ESTIMATED)
Number of arms: 3.0
Start date: 2018-04-19
Primary completion date: 2021-06-30
Completion date: 2021-08-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04208516: Continuous Nerve Block Block vs Combination of Single Block Plus Intravenous Lidocaine for Postoperative Pain.
Official title: A Prospective, Randomized, Active-Comparator, Open-Label, Non-Inferiority Study of the Efficacy of Continuous Nerve Block vs Single Block Plus Intravenous Lidocaine for Postoperative Pain.
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Recruitment was unable to be obtained in a timely fashion, so the study was stopped.
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-26
Primary completion date: 2022-08-18
Completion date: 2022-08-18
Limitations and caveats: We were not able to enroll enough subjects in a timely manner and our enrollment numbers did not reach the goal of our pilot study.
Plan to share individual participant data: NO
Clinical trial NCT03661411: Antiplatelet vs R-tPA for Acute Mild Ischemic Stroke
Official title: Antiplatelet vs R-tPA for Acute Mild Ischemic Stroke: a Prospective, Random, Blinded Assessment of Outcome and Open Label Multi-center Study
Acronym: ARAMIS
Sponsor: General Hospital of Shenyang Military Region (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 760.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-17
Primary completion date: 2022-07-18
Completion date: 2022-07-18
Plan to share individual participant data: NO
Clinical trial NCT03982992: Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab
Official title: Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab in Patients With Treatment-Resistant Mixed Chimerism or Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia After Allogeneic Stem Cell Transplantation
Acronym: DLI-TARGET
Sponsor: Ludwig-Maximilians - University of Munich (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Lack of potential study subjects due to a change of standard of care treatment outside of clinical trials.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-06-01
Primary completion date: 2021-05-31
Completion date: 2021-11-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT01224106: A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Official title: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Acronym: Scarlet Road
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 799.0 (ACTUAL)
Number of arms: 5.0
Start date: 2010-11-30
Primary completion date: 2020-09-10
Completion date: 2020-09-10
Baseline population: A total of 797 participants were enrolled into the Double-Blind Treatment phase of this study and the entire study. A subset (154) of these participants moved into the OLE phase of this study.
Clinical trial NCT04049175: Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma
Official title: A 52 Week, Randomised, Double Blind, Multinational, Multicentre, 4-arm Parallel Group Trial to Assess the Efficacy and Safety of 3 Doses of CHF 6532 Compared to Placebo on Top of Standard of Care in Patients With Uncontrolled Severe Eosinophilic Asthma
Acronym: PERSEA
Sponsor: Chiesi Farmaceutici S.p.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: An interim analysis run by an independent data monitoring committee (DMC) to assess futility met the protocol-defined futility rules. The DMC recommended to stop the study for futility. The Sponsor issued a notification of early study termination.
Enrollment: 810.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-08-28
Primary completion date: 2020-10-19
Completion date: 2021-02-01
Plan to share individual participant data: NO
Clinical trial NCT04842331: PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)
Official title: A Randomised Multicentre Post-exposure Prophylaxis Clinical Trial Evaluating RESP301, an Inhaled Therapy for Treatment of Lung Infections, for Prevention of Onward Transmission of Viral Infections Including SARS-CoV-2 to Household Members
Acronym: PREVENT
Sponsor: Thirty Respiratory Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: A combination of factors, including the dynamic nature of the COVID-19 pandemic and the successful vaccination program, has resulted in a very sharp decline in the number of patients with COVID-19
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-30
Primary completion date: 2022-01-31
Completion date: 2022-01-31